{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"what-are-peptides-ibd","title":"What Are Peptides for IBD","body":"## What's breaking down\n\nInflammatory bowel disease involves ongoing damage to the intestinal lining. Chronic inflammation erodes the mucosal barrier. This leads to ulcers, fistulas, and poor healing of surgical connections. The balance tips toward degeneration when repair mechanisms cannot keep pace with ongoing injury from immune activity and environmental triggers. Standard approaches often focus on suppressing inflammation. Repair-focused research looks at compounds that may support the gut's own healing processes instead.\n\n## Why BPC-157 might help you\n\nIf your IBD features persistent mucosal ulcers and fistulas, BPC-157 has been studied in rat models of colitis and fistula formation. In those setups, the peptide accelerated closure of defects and improved tissue strength at anastomosis sites. If inflammation drives ongoing breakdown, animal data show reduced cytokine activity and better endothelial protection in damaged gut segments. If you have short-bowel or poor wound healing after surgery, the same rat studies reported faster recovery of intestinal continuity and collagen deposition. These outcomes point to cytoprotective effects that stabilize the lining under stress.\n\n## How these fit together\n\nThis article focuses on a single compound. BPC-157 targets mucosal repair layers directly. Other peptides sometimes discussed in broader stacks address immune modulation or vascular support, but they sit outside the current evidence scope for IBD.\n\n## What the evidence actually shows\n\nHuman tier: Early phase II trials (PL-10, PLD-116, PL14736) from the 1990s and 2000s tested BPC-157 in ulcerative colitis patients. Proponents reported safety and some benefit, yet detailed peer-reviewed results with large cohorts remain unpublished. No robust, modern randomized controlled trials confirm remission rates or endoscopic healing in IBD. Preclinical tier: Over 30 rat studies document healing in cysteamine colitis, NSAID injury, colocutaneous fistulas, and ileoileal anastomosis models. Doses as low as 10 ng/kg improved outcomes when given orally or intraperitoneally. These prove consistent tissue repair in controlled animal settings but do not prove the same in humans. Anecdotal tier: Reddit threads in r/UlcerativeColitis contain mixed reports. Some users describe reduced flares after oral or injectable use; others report no change after months of use and thousands of dollars spent. X posts echo similar personal stories without controlled verification.\n\n## What scientists say\n\nResearchers from the originating group describe BPC-157 as stable in human gastric juice for over 24 hours and effective across upper and lower GI tract models. Reviews note its interaction with nitric oxide pathways and growth factor expression that may aid angiogenesis and collagen formation. Independent gastroenterologists emphasize the absence of large-scale published human IBD data and advise against routine recommendation pending further trials. Toxicology studies in animals reached no lethal dose, supporting a wide safety margin in those models.\n\n## What people say on Reddit\n\nUsers share experiences ranging from noticeable symptom relief within weeks to complete lack of effect. Several threads caution that BPC-157 lacks FDA approval and published phase III data for IBD. One post referenced an open FDA docket and urged patients with positive experiences to submit comments. Others note concurrent use with conventional therapies and stress the importance of monitoring.\n\n## What people say on X\n\nPosts frequently link BPC-157 to gut repair claims based on animal literature. Some individuals report personal remission stories; others highlight ongoing clinical trial gaps or potential regulatory scrutiny. Discussions often reference the same rat fistula and colitis papers cited in scientific reviews.\n\n## What we do not know\n\nLong-term human safety beyond short trial windows remains uncharacterized. Optimal delivery route, duration, and patient selection criteria for IBD subtypes lack definition. Whether observed rat healing translates to sustained endoscopic remission in people is untested in adequately powered studies. Interaction with current IBD biologics or small molecules is undocumented.\n\n## Safety and limits\n\nAnimal data indicate low toxicity. Human phase II reports from decades ago claimed no side effects, but these lack independent confirmation. BPC-157 is not FDA-approved for any indication. Regulatory bodies continue to evaluate its status. Individuals considering research compounds should consult clinicians and review current legal status in their jurisdiction.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/what-are-peptides-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"BPC-157 accelerated healing in rat models of colitis, fistulas, and intestinal anastomosis.","section":"Why BPC-157 might help you","tier":"preclinical","source_ids":["s9","s10","s16"],"source_status":"sourced","why_material":"Demonstrates repair pathway activity in IBD-relevant injury models.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Early phase II trials tested BPC-157 in ulcerative colitis but detailed large-scale published results are unavailable.","section":"What the evidence actually shows","tier":"human","source_ids":["s14","s15","s20"],"source_status":"sourced","why_material":"Clarifies the limited scope of existing human data versus claims.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Over thirty rat studies show consistent cytoprotective and healing effects in GI damage models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s10"],"source_status":"sourced","why_material":"Quantifies the preclinical evidence base.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report mixed outcomes with BPC-157 for UC symptoms, including both improvement and no effect.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s24","s25","s26"],"source_status":"sourced","why_material":"Captures real-world user experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"BPC-157 remains unapproved by the FDA with no robust published phase III IBD efficacy data.","section":"Safety and limits","tier":"human","source_ids":["s15","s6"],"source_status":"sourced","why_material":"Sets regulatory and evidence boundaries clearly.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22300085/","title":"Stable gastric pentadecapeptide BPC 157","quote":"BPC 157 ... may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects.","summary":"Review highlighting GI tract stability and potential IBD relevance.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"97d3049c196ddbacc7b0705ebbf947bd96c83e3cee13a37b7d8ca6d791606144"},{"id":"s10","type":"pubmed","url":"https://journals.lww.com/ajg/fulltext/2025/10002/s808_oral_peptide_bpc_157_an_emerging_adjunct_to.809.aspx","title":"S808 Oral Peptide BPC-157—An Emerging Adjunct to...","quote":"In preclinical models, BPC-157 improved functional and structural outcomes in inflammatory bowel disease...","summary":"Systematic review of 36 studies noting preclinical GI healing data and lack of clinical safety data.","claim_ids":["c1","c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"http_403","quote_status":"unverified","prev":"97d3049c196ddbacc7b0705ebbf947bd96c83e3cee13a37b7d8ca6d791606144","hash":"c1d38f94c2acfe8bba0970d31fc485f74ee37507f0a41a8832efebfdec4b5d2b"},{"id":"s14","type":"other","url":"https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger","title":"BPC-157: Miracle Healing Peptide or Hidden Danger?","quote":"Older European trials: BPC-157’s discoverers in Europe have claimed success in early clinical trials for inflammatory bowel disease in the 1990s.","summary":"Notes phase II UC mentions but questions publication quality.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"c1d38f94c2acfe8bba0970d31fc485f74ee37507f0a41a8832efebfdec4b5d2b","hash":"1e58f24e89b25594daedcf9cb74c0b175251e4a49e532e9cda0615651c7bec0f"},{"id":"s15","type":"other","url":"https://www.guthealthdubai.com/can-bpc-157-heal-your-gut-a-dubai-gut-doctors-honest-opinion/","title":"Can BPC 157 Heal Your Gut?","quote":"There are zero robust, published human clinical trials for IBD.","summary":"Gastroenterologist review emphasizing absence of high-quality human IBD data.","claim_ids":["c2","c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"verified","prev":"1e58f24e89b25594daedcf9cb74c0b175251e4a49e532e9cda0615651c7bec0f","hash":"b1ba28246e1d612b9915898ded63e760422ebbf42a5f47bfa8be8b7d99531a01"},{"id":"s16","type":"pubmed","url":"https://jpp.krakow.pl/journal/archive/10_13/articles/09_article.html","title":"stable gastric pentadecapeptide bpc 157 heals cysteamine...","quote":"BPC 157 induced an efficient healing of both at the same time...","summary":"Rat study linking colitis healing to broader IBD and MS models.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"b1ba28246e1d612b9915898ded63e760422ebbf42a5f47bfa8be8b7d99531a01","hash":"711164f18a635497f2457fd3fbfeccd57c2e7a5ed4cbad8272b376d00c70e160"},{"id":"s20","type":"other","url":"https://www.youtube.com/watch?v=HfJH-qIzeqA","title":"Can BPC-157 Fix Your Gut and Joints?","quote":"The most notable human studies involving BPC-157 pertain to its potential treatment for inflammatory bowel disease (IBD), particularly mild to moderate ulcerative colitis.","summary":"Video summary referencing old Pliva trials.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"http_429","quote_status":"unverified","prev":"711164f18a635497f2457fd3fbfeccd57c2e7a5ed4cbad8272b376d00c70e160","hash":"828d7b0dd4187422253c3678c45f943d4d97af9b3aa59045a216c5a95730a02f"},{"id":"s24","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1qpjb64/any_tried_bpc_157_peptides/","title":"Any tried BPC 157 peptides?","quote":"There is absolutely no reliable evidence this works in humans for management of IBD, no published phase II or greater clinical trials...","summary":"Thread discussing lack of evidence and user skepticism.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"828d7b0dd4187422253c3678c45f943d4d97af9b3aa59045a216c5a95730a02f","hash":"dc5ba5ff0ef67c9fe95451b911e80002b30f436948871261456a9840f365928a"},{"id":"s25","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1cd99ol/battling_ulcerative_colitis_with_bpc157/","title":"Battling Ulcerative Colitis with BPC-157","quote":"Anti-inflammatory properties: BPC-157 has been shown to reduce inflammation... Limited clinical trials...","summary":"User post and comments on anecdotal use and trial limitations.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"dc5ba5ff0ef67c9fe95451b911e80002b30f436948871261456a9840f365928a","hash":"1cfacd76b1a9b88e927ea83c8182dc8545a11dc21c5d8b3920bae90e42207b39"},{"id":"s26","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1stmgxs/if_bpc157_helped_your_uc_please_comment_on_this/","title":"If BPC-157 helped your UC, PLEASE comment on this FDA...","quote":"Within a few weeks I noticed real improvement, and after about 2 months, I was back in remission.","summary":"Personal remission anecdote alongside calls for public input.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"1cfacd76b1a9b88e927ea83c8182dc8545a11dc21c5d8b3920bae90e42207b39","hash":"6e3af8913051ffe06a9a90cdf719965354a7f9a2a257a433862149f987d91554"},{"id":"s6","type":"other","url":"https://www.droracle.ai/articles/298681/is-bpc-157-body-protection-compound-157-effective-as","title":"BPC 157 is Not Recommended for Crohn's Disease...","quote":"Most studies are limited to animal models · Only phase II clinical trials for inflammatory bowel disease have been conducted","summary":"Summary of evidence gaps and regulatory status.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"6e3af8913051ffe06a9a90cdf719965354a7f9a2a257a433862149f987d91554","hash":"269a78da0123a30ff39a64eb68aefda8b0daa36eb6cd46e40583953c8c572e4f"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T21:57:50.870Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"What Are Peptides for IBD","register":"source_ledger","body":"## What's breaking down\n\nInflammatory bowel disease involves ongoing damage to the intestinal lining. Chronic inflammation erodes the mucosal barrier. This leads to ulcers, fistulas, and poor healing of surgical connections. The balance tips toward degeneration when repair mechanisms cannot keep pace with ongoing injury from immune activity and environmental triggers. Standard approaches often focus on suppressing inflammation. Repair-focused research looks at compounds that may support the gut's own healing processes instead.\n\n## Why BPC-157 might help you\n\nIf your IBD features persistent mucosal ulcers and fistulas, BPC-157 has been studied in rat models of colitis and fistula formation. In those setups, the peptide accelerated closure of defects and improved tissue strength at anastomosis sites. If inflammation drives ongoing breakdown, animal data show reduced cytokine activity and better endothelial protection in damaged gut segments. If you have short-bowel or poor wound healing after surgery, the same rat studies reported faster recovery of intestinal continuity and collagen deposition. These outcomes point to cytoprotective effects that stabilize the lining under stress.\n\n## How these fit together\n\nThis article focuses on a single compound. BPC-157 targets mucosal repair layers directly. Other peptides sometimes discussed in broader stacks address immune modulation or vascular support, but they sit outside the current evidence scope for IBD.\n\n## What the evidence actually shows\n\nHuman tier: Early phase II trials (PL-10, PLD-116, PL14736) from the 1990s and 2000s tested BPC-157 in ulcerative colitis patients. Proponents reported safety and some benefit, yet detailed peer-reviewed results with large cohorts remain unpublished. No robust, modern randomized controlled trials confirm remission rates or endoscopic healing in IBD. Preclinical tier: Over 30 rat studies document healing in cysteamine colitis, NSAID injury, colocutaneous fistulas, and ileoileal anastomosis models. Doses as low as 10 ng/kg improved outcomes when given orally or intraperitoneally. These prove consistent tissue repair in controlled animal settings but do not prove the same in humans. Anecdotal tier: Reddit threads in r/UlcerativeColitis contain mixed reports. Some users describe reduced flares after oral or injectable use; others report no change after months of use and thousands of dollars spent. X posts echo similar personal stories without controlled verification.\n\n## What scientists say\n\nResearchers from the originating group describe BPC-157 as stable in human gastric juice for over 24 hours and effective across upper and lower GI tract models. Reviews note its interaction with nitric oxide pathways and growth factor expression that may aid angiogenesis and collagen formation. Independent gastroenterologists emphasize the absence of large-scale published human IBD data and advise against routine recommendation pending further trials. Toxicology studies in animals reached no lethal dose, supporting a wide safety margin in those models.\n\n## What people say on Reddit\n\nUsers share experiences ranging from noticeable symptom relief within weeks to complete lack of effect. Several threads caution that BPC-157 lacks FDA approval and published phase III data for IBD. One post referenced an open FDA docket and urged patients with positive experiences to submit comments. Others note concurrent use with conventional therapies and stress the importance of monitoring.\n\n## What people say on X\n\nPosts frequently link BPC-157 to gut repair claims based on animal literature. Some individuals report personal remission stories; others highlight ongoing clinical trial gaps or potential regulatory scrutiny. Discussions often reference the same rat fistula and colitis papers cited in scientific reviews.\n\n## What we do not know\n\nLong-term human safety beyond short trial windows remains uncharacterized. Optimal delivery route, duration, and patient selection criteria for IBD subtypes lack definition. Whether observed rat healing translates to sustained endoscopic remission in people is untested in adequately powered studies. Interaction with current IBD biologics or small molecules is undocumented.\n\n## Safety and limits\n\nAnimal data indicate low toxicity. Human phase II reports from decades ago claimed no side effects, but these lack independent confirmation. BPC-157 is not FDA-approved for any indication. Regulatory bodies continue to evaluate its status. Individuals considering research compounds should consult clinicians and review current legal status in their jurisdiction.","claims":[{"id":"c1","text":"BPC-157 accelerated healing in rat models of colitis, fistulas, and intestinal anastomosis.","section":"Why BPC-157 might help you","tier":"preclinical","source_ids":["s9","s10","s16"],"source_status":"sourced","why_material":"Demonstrates repair pathway activity in IBD-relevant injury models.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Early phase II trials tested BPC-157 in ulcerative colitis but detailed large-scale published results are unavailable.","section":"What the evidence actually shows","tier":"human","source_ids":["s14","s15","s20"],"source_status":"sourced","why_material":"Clarifies the limited scope of existing human data versus claims.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Over thirty rat studies show consistent cytoprotective and healing effects in GI damage models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s10"],"source_status":"sourced","why_material":"Quantifies the preclinical evidence base.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report mixed outcomes with BPC-157 for UC symptoms, including both improvement and no effect.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s24","s25","s26"],"source_status":"sourced","why_material":"Captures real-world user experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"BPC-157 remains unapproved by the FDA with no robust published phase III IBD efficacy data.","section":"Safety and limits","tier":"human","source_ids":["s15","s6"],"source_status":"sourced","why_material":"Sets regulatory and evidence boundaries clearly.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22300085/","title":"Stable gastric pentadecapeptide BPC 157","quote":"BPC 157 ... may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects.","link_status":"ok","quote_status":"unverified"},{"id":"s10","type":"pubmed","url":"https://journals.lww.com/ajg/fulltext/2025/10002/s808_oral_peptide_bpc_157_an_emerging_adjunct_to.809.aspx","title":"S808 Oral Peptide BPC-157—An Emerging Adjunct to...","quote":"In preclinical models, BPC-157 improved functional and structural outcomes in inflammatory bowel disease...","link_status":"http_403","quote_status":"unverified"},{"id":"s14","type":"other","url":"https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger","title":"BPC-157: Miracle Healing Peptide or Hidden Danger?","quote":"Older European trials: BPC-157’s discoverers in Europe have claimed success in early clinical trials for inflammatory bowel disease in the 1990s.","link_status":"ok","quote_status":"unverified"},{"id":"s15","type":"other","url":"https://www.guthealthdubai.com/can-bpc-157-heal-your-gut-a-dubai-gut-doctors-honest-opinion/","title":"Can BPC 157 Heal Your Gut?","quote":"There are zero robust, published human clinical trials for IBD.","link_status":"ok","quote_status":"verified"},{"id":"s16","type":"pubmed","url":"https://jpp.krakow.pl/journal/archive/10_13/articles/09_article.html","title":"stable gastric pentadecapeptide bpc 157 heals cysteamine...","quote":"BPC 157 induced an efficient healing of both at the same time...","link_status":"ok","quote_status":"unverified"},{"id":"s20","type":"other","url":"https://www.youtube.com/watch?v=HfJH-qIzeqA","title":"Can BPC-157 Fix Your Gut and Joints?","quote":"The most notable human studies involving BPC-157 pertain to its potential treatment for inflammatory bowel disease (IBD), particularly mild to moderate ulcerative colitis.","link_status":"http_429","quote_status":"unverified"},{"id":"s24","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1qpjb64/any_tried_bpc_157_peptides/","title":"Any tried BPC 157 peptides?","quote":"There is absolutely no reliable evidence this works in humans for management of IBD, no published phase II or greater clinical trials...","link_status":"ok","quote_status":"unverified"},{"id":"s25","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1cd99ol/battling_ulcerative_colitis_with_bpc157/","title":"Battling Ulcerative Colitis with BPC-157","quote":"Anti-inflammatory properties: BPC-157 has been shown to reduce inflammation... Limited clinical trials...","link_status":"ok","quote_status":"unverified"},{"id":"s26","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1stmgxs/if_bpc157_helped_your_uc_please_comment_on_this/","title":"If BPC-157 helped your UC, PLEASE comment on this FDA...","quote":"Within a few weeks I noticed real improvement, and after about 2 months, I was back in remission.","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"other","url":"https://www.droracle.ai/articles/298681/is-bpc-157-body-protection-compound-157-effective-as","title":"BPC 157 is Not Recommended for Crohn's Disease...","quote":"Most studies are limited to animal models · Only phase II clinical trials for inflammatory bowel disease have been conducted","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":17466,"tokens_out":3021,"cost":0.029385,"prev_hash":"genesis","hash":"0ae632aa0172712bf6bb24e94b6f0d52beac4fa066aa5b96e6e8f589a598a037"}],"provenance":[{"ts":"2026-06-29T21:57:50.870Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: What Are Peptides for Ibd\nSlug: what-are-peptides-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\",\"section_headings\":[\"What's breaking down\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_sensitive + GLP-1 peptide: include ~4 lb spinal load per 1 lb lost when relevant.\",\"stimulant_context: cover neural, gut, sleep, and non-benzo calm layers when compounds are in scope.\",\"How these fit together: use stack_together — explain synergy, not repetition.\"]}","response":"{\"slug\":\"what-are-peptides-ibd\",\"title\":\"What Are Peptides for IBD\",\"body\":\"## What's breaking down\\n\\nInflammatory bowel disease involves ongoing damage to the intestinal lining. Chronic inflammation erodes the mucosal barrier. This leads to ulcers, fistulas, and poor healing of surgical connections. The balance tips toward degeneration when repair mechanisms cannot keep pace with ongoing injury from immune activity and environmental triggers. Standard approaches often focus on suppressing inflammation. Repair-focused research looks at compounds that may support the gut's own healing processes instead.\\n\\n## Why BPC-157 might help you\\n\\nIf your IBD features persistent mucosal ulcers and fistulas, BPC-157 has been studied in rat models of colitis and fistula formation. In those setups, the peptide accelerated closure of defects and improved tissue strength at anastomosis sites. If inflammation drives ongoing breakdown, animal data show reduced cytokine activity and better endothelial protection in damaged gut segments. If you have short-bowel or poor wound healing after surgery, the same rat studies reported faster recovery of intestinal continuity and collagen deposition. These outcomes point to cytoprotective effects that stabilize the lining under stress.\\n\\n## How these fit together\\n\\nThis article focuses on a single compound. BPC-157 targets mucosal repair layers directly. Other peptides sometimes discussed in broader stacks address immune modulation or vascular support, but they sit outside the current evidence scope for IBD.\\n\\n## What the evidence actually shows\\n\\nHuman tier: Early phase II trials (PL-10, PLD-116, PL14736) from the 1990s and 2000s tested BPC-157 in ulcerative colitis patients. Proponents reported safety and some benefit, yet detailed peer-reviewed results with large cohorts remain unpublished. No robust, modern randomized controlled trials confirm remission rates or endoscopic healing in IBD. Preclinical tier: Over 30 rat studies document","tokens_in":17466,"tokens_out":3021,"cost":0,"prev":"genesis","hash":"765761eb457793e80615bb1c9368b51466716e8486b4efc789547952b7fa10d7"},{"ts":"2026-07-17T02:43:32.414Z","model":"owner","action":"voxel_divide","prompt":"","input":"what-are-peptides-ibd","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"765761eb457793e80615bb1c9368b51466716e8486b4efc789547952b7fa10d7","hash":"0fca23d9f867bd56d5cfeb6392e3227efa66df8b86737a90cf5708450ba88789"}],"energy":{"passes":2,"tokens_in":17466,"tokens_out":3021,"tokens_total":20487,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"0fca23d9f867bd56d5cfeb6392e3227efa66df8b86737a90cf5708450ba88789"},"posted_at":"2026-06-29T21:33:57.381Z","created_at":"2026-06-29T21:33:57.381Z","updated_at":"2026-07-17T02:43:32.414Z","machine":{"shape":"article.machine/v1","slug":"what-are-peptides-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/what-are-peptides-ibd","json":"https://miscsubjects.com/api/articles/what-are-peptides-ibd","bundle":"https://miscsubjects.com/api/articles/what-are-peptides-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":10,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/what-are-peptides-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=what-are-peptides-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/what-are-peptides-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"what-are-peptides-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/what-are-peptides-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/what-are-peptides-ibd","json":"/api/articles/what-are-peptides-ibd","markdown":"/api/articles/what-are-peptides-ibd/bundle?format=markdown","skill":"/api/articles/what-are-peptides-ibd/skill","topology":"/api/articles/what-are-peptides-ibd/topology","versions":"/api/articles/what-are-peptides-ibd/revisions","invocations":"/api/articles/what-are-peptides-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"what-are-peptides-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"f313343e9fc6543df1ca1da0ba6ee1849dc2572dc554c93d7f36482d7e48dbf3","object":{"object_type":"article-object","identity":{"id":"article:what-are-peptides-ibd","slug":"what-are-peptides-ibd","title":"What Are Peptides for IBD"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/what-are-peptides-ibd","role":"explain","audience":"human"},"skill":{"route":"/api/articles/what-are-peptides-ibd/skill","role":"direct behavior","audience":"model","content":"---\nname: what-are-peptides-ibd\ndescription: Apply the What Are Peptides for IBD article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# What Are Peptides for IBD\n\nThis Skill is the behavioral expression of [the canonical article](/a/what-are-peptides-ibd). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/what-are-peptides-ibd.\n- Read claims and relationships at /api/articles/what-are-peptides-ibd/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Inflammatory bowel disease involves ongoing damage to the intestinal lining. Chronic inflammation erodes the mucosal barrier. This leads to ulcers, fistulas, and poor healing of surgical connections. The balance tips to\n\n## Representations\n\n- Human: /a/what-are-peptides-ibd\n- JSON: /api/articles/what-are-peptides-ibd\n- Relationships: /api/articles/what-are-peptides-ibd/topology\n- History: /api/articles/what-are-peptides-ibd/revisions\n"},"json":{"route":"/api/articles/what-are-peptides-ibd","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/what-are-peptides-ibd/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","what","are","peptides","ibd"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/what-are-peptides-ibd/invocations?status=success","failure_events":"/api/articles/what-are-peptides-ibd/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"what-are-peptides-ibd","title":"What Are Peptides for IBD","body":"## What's breaking down\n\nInflammatory bowel disease involves ongoing damage to the intestinal lining. Chronic inflammation erodes the mucosal barrier. This leads to ulcers, fistulas, and poor healing of surgical connections. The balance tips toward degeneration when repair mechanisms cannot keep pace with ongoing injury from immune activity and environmental triggers. Standard approaches often focus on suppressing inflammation. Repair-focused research looks at compounds that may support the gut's own healing processes instead.\n\n## Why BPC-157 might help you\n\nIf your IBD features persistent mucosal ulcers and fistulas, BPC-157 has been studied in rat models of colitis and fistula formation. In those setups, the peptide accelerated closure of defects and improved tissue strength at anastomosis sites. If inflammation drives ongoing breakdown, animal data show reduced cytokine activity and better endothelial protection in damaged gut segments. If you have short-bowel or poor wound healing after surgery, the same rat studies reported faster recovery of intestinal continuity and collagen deposition. These outcomes point to cytoprotective effects that stabilize the lining under stress.\n\n## How these fit together\n\nThis article focuses on a single compound. BPC-157 targets mucosal repair layers directly. Other peptides sometimes discussed in broader stacks address immune modulation or vascular support, but they sit outside the current evidence scope for IBD.\n\n## What the evidence actually shows\n\nHuman tier: Early phase II trials (PL-10, PLD-116, PL14736) from the 1990s and 2000s tested BPC-157 in ulcerative colitis patients. Proponents reported safety and some benefit, yet detailed peer-reviewed results with large cohorts remain unpublished. No robust, modern randomized controlled trials confirm remission rates or endoscopic healing in IBD. Preclinical tier: Over 30 rat studies document healing in cysteamine colitis, NSAID injury, colocutaneous fistulas, and ileoileal anastomosis models. Doses as low as 10 ng/kg improved outcomes when given orally or intraperitoneally. These prove consistent tissue repair in controlled animal settings but do not prove the same in humans. Anecdotal tier: Reddit threads in r/UlcerativeColitis contain mixed reports. Some users describe reduced flares after oral or injectable use; others report no change after months of use and thousands of dollars spent. X posts echo similar personal stories without controlled verification.\n\n## What scientists say\n\nResearchers from the originating group describe BPC-157 as stable in human gastric juice for over 24 hours and effective across upper and lower GI tract models. Reviews note its interaction with nitric oxide pathways and growth factor expression that may aid angiogenesis and collagen formation. Independent gastroenterologists emphasize the absence of large-scale published human IBD data and advise against routine recommendation pending further trials. Toxicology studies in animals reached no lethal dose, supporting a wide safety margin in those models.\n\n## What people say on Reddit\n\nUsers share experiences ranging from noticeable symptom relief within weeks to complete lack of effect. Several threads caution that BPC-157 lacks FDA approval and published phase III data for IBD. One post referenced an open FDA docket and urged patients with positive experiences to submit comments. Others note concurrent use with conventional therapies and stress the importance of monitoring.\n\n## What people say on X\n\nPosts frequently link BPC-157 to gut repair claims based on animal literature. Some individuals report personal remission stories; others highlight ongoing clinical trial gaps or potential regulatory scrutiny. Discussions often reference the same rat fistula and colitis papers cited in scientific reviews.\n\n## What we do not know\n\nLong-term human safety beyond short trial windows remains uncharacterized. Optimal delivery route, duration, and patient selection criteria for IBD subtypes lack definition. Whether observed rat healing translates to sustained endoscopic remission in people is untested in adequately powered studies. Interaction with current IBD biologics or small molecules is undocumented.\n\n## Safety and limits\n\nAnimal data indicate low toxicity. Human phase II reports from decades ago claimed no side effects, but these lack independent confirmation. BPC-157 is not FDA-approved for any indication. Regulatory bodies continue to evaluate its status. Individuals considering research compounds should consult clinicians and review current legal status in their jurisdiction.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/what-are-peptides-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"BPC-157 accelerated healing in rat models of colitis, fistulas, and intestinal anastomosis.","section":"Why BPC-157 might help you","tier":"preclinical","source_ids":["s9","s10","s16"],"source_status":"sourced","why_material":"Demonstrates repair pathway activity in IBD-relevant injury models.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Early phase II trials tested BPC-157 in ulcerative colitis but detailed large-scale published results are unavailable.","section":"What the evidence actually shows","tier":"human","source_ids":["s14","s15","s20"],"source_status":"sourced","why_material":"Clarifies the limited scope of existing human data versus claims.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Over thirty rat studies show consistent cytoprotective and healing effects in GI damage models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s10"],"source_status":"sourced","why_material":"Quantifies the preclinical evidence base.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report mixed outcomes with BPC-157 for UC symptoms, including both improvement and no effect.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s24","s25","s26"],"source_status":"sourced","why_material":"Captures real-world user experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"BPC-157 remains unapproved by the FDA with no robust published phase III IBD efficacy data.","section":"Safety and limits","tier":"human","source_ids":["s15","s6"],"source_status":"sourced","why_material":"Sets regulatory and evidence boundaries clearly.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22300085/","title":"Stable gastric pentadecapeptide BPC 157","quote":"BPC 157 ... may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects.","summary":"Review highlighting GI tract stability and potential IBD relevance.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"97d3049c196ddbacc7b0705ebbf947bd96c83e3cee13a37b7d8ca6d791606144"},{"id":"s10","type":"pubmed","url":"https://journals.lww.com/ajg/fulltext/2025/10002/s808_oral_peptide_bpc_157_an_emerging_adjunct_to.809.aspx","title":"S808 Oral Peptide BPC-157—An Emerging Adjunct to...","quote":"In preclinical models, BPC-157 improved functional and structural outcomes in inflammatory bowel disease...","summary":"Systematic review of 36 studies noting preclinical GI healing data and lack of clinical safety data.","claim_ids":["c1","c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"http_403","quote_status":"unverified","prev":"97d3049c196ddbacc7b0705ebbf947bd96c83e3cee13a37b7d8ca6d791606144","hash":"c1d38f94c2acfe8bba0970d31fc485f74ee37507f0a41a8832efebfdec4b5d2b"},{"id":"s14","type":"other","url":"https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger","title":"BPC-157: Miracle Healing Peptide or Hidden Danger?","quote":"Older European trials: BPC-157’s discoverers in Europe have claimed success in early clinical trials for inflammatory bowel disease in the 1990s.","summary":"Notes phase II UC mentions but questions publication quality.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"c1d38f94c2acfe8bba0970d31fc485f74ee37507f0a41a8832efebfdec4b5d2b","hash":"1e58f24e89b25594daedcf9cb74c0b175251e4a49e532e9cda0615651c7bec0f"},{"id":"s15","type":"other","url":"https://www.guthealthdubai.com/can-bpc-157-heal-your-gut-a-dubai-gut-doctors-honest-opinion/","title":"Can BPC 157 Heal Your Gut?","quote":"There are zero robust, published human clinical trials for IBD.","summary":"Gastroenterologist review emphasizing absence of high-quality human IBD data.","claim_ids":["c2","c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"verified","prev":"1e58f24e89b25594daedcf9cb74c0b175251e4a49e532e9cda0615651c7bec0f","hash":"b1ba28246e1d612b9915898ded63e760422ebbf42a5f47bfa8be8b7d99531a01"},{"id":"s16","type":"pubmed","url":"https://jpp.krakow.pl/journal/archive/10_13/articles/09_article.html","title":"stable gastric pentadecapeptide bpc 157 heals cysteamine...","quote":"BPC 157 induced an efficient healing of both at the same time...","summary":"Rat study linking colitis healing to broader IBD and MS models.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"b1ba28246e1d612b9915898ded63e760422ebbf42a5f47bfa8be8b7d99531a01","hash":"711164f18a635497f2457fd3fbfeccd57c2e7a5ed4cbad8272b376d00c70e160"},{"id":"s20","type":"other","url":"https://www.youtube.com/watch?v=HfJH-qIzeqA","title":"Can BPC-157 Fix Your Gut and Joints?","quote":"The most notable human studies involving BPC-157 pertain to its potential treatment for inflammatory bowel disease (IBD), particularly mild to moderate ulcerative colitis.","summary":"Video summary referencing old Pliva trials.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"http_429","quote_status":"unverified","prev":"711164f18a635497f2457fd3fbfeccd57c2e7a5ed4cbad8272b376d00c70e160","hash":"828d7b0dd4187422253c3678c45f943d4d97af9b3aa59045a216c5a95730a02f"},{"id":"s24","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1qpjb64/any_tried_bpc_157_peptides/","title":"Any tried BPC 157 peptides?","quote":"There is absolutely no reliable evidence this works in humans for management of IBD, no published phase II or greater clinical trials...","summary":"Thread discussing lack of evidence and user skepticism.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"828d7b0dd4187422253c3678c45f943d4d97af9b3aa59045a216c5a95730a02f","hash":"dc5ba5ff0ef67c9fe95451b911e80002b30f436948871261456a9840f365928a"},{"id":"s25","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1cd99ol/battling_ulcerative_colitis_with_bpc157/","title":"Battling Ulcerative Colitis with BPC-157","quote":"Anti-inflammatory properties: BPC-157 has been shown to reduce inflammation... Limited clinical trials...","summary":"User post and comments on anecdotal use and trial limitations.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"dc5ba5ff0ef67c9fe95451b911e80002b30f436948871261456a9840f365928a","hash":"1cfacd76b1a9b88e927ea83c8182dc8545a11dc21c5d8b3920bae90e42207b39"},{"id":"s26","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1stmgxs/if_bpc157_helped_your_uc_please_comment_on_this/","title":"If BPC-157 helped your UC, PLEASE comment on this FDA...","quote":"Within a few weeks I noticed real improvement, and after about 2 months, I was back in remission.","summary":"Personal remission anecdote alongside calls for public input.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"1cfacd76b1a9b88e927ea83c8182dc8545a11dc21c5d8b3920bae90e42207b39","hash":"6e3af8913051ffe06a9a90cdf719965354a7f9a2a257a433862149f987d91554"},{"id":"s6","type":"other","url":"https://www.droracle.ai/articles/298681/is-bpc-157-body-protection-compound-157-effective-as","title":"BPC 157 is Not Recommended for Crohn's Disease...","quote":"Most studies are limited to animal models · Only phase II clinical trials for inflammatory bowel disease have been conducted","summary":"Summary of evidence gaps and regulatory status.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:57:47.735Z","link_status":"ok","quote_status":"unverified","prev":"6e3af8913051ffe06a9a90cdf719965354a7f9a2a257a433862149f987d91554","hash":"269a78da0123a30ff39a64eb68aefda8b0daa36eb6cd46e40583953c8c572e4f"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T21:57:50.870Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"What Are Peptides for IBD","register":"source_ledger","body":"## What's breaking down\n\nInflammatory bowel disease involves ongoing damage to the intestinal lining. Chronic inflammation erodes the mucosal barrier. This leads to ulcers, fistulas, and poor healing of surgical connections. The balance tips toward degeneration when repair mechanisms cannot keep pace with ongoing injury from immune activity and environmental triggers. Standard approaches often focus on suppressing inflammation. Repair-focused research looks at compounds that may support the gut's own healing processes instead.\n\n## Why BPC-157 might help you\n\nIf your IBD features persistent mucosal ulcers and fistulas, BPC-157 has been studied in rat models of colitis and fistula formation. In those setups, the peptide accelerated closure of defects and improved tissue strength at anastomosis sites. If inflammation drives ongoing breakdown, animal data show reduced cytokine activity and better endothelial protection in damaged gut segments. If you have short-bowel or poor wound healing after surgery, the same rat studies reported faster recovery of intestinal continuity and collagen deposition. These outcomes point to cytoprotective effects that stabilize the lining under stress.\n\n## How these fit together\n\nThis article focuses on a single compound. BPC-157 targets mucosal repair layers directly. Other peptides sometimes discussed in broader stacks address immune modulation or vascular support, but they sit outside the current evidence scope for IBD.\n\n## What the evidence actually shows\n\nHuman tier: Early phase II trials (PL-10, PLD-116, PL14736) from the 1990s and 2000s tested BPC-157 in ulcerative colitis patients. Proponents reported safety and some benefit, yet detailed peer-reviewed results with large cohorts remain unpublished. No robust, modern randomized controlled trials confirm remission rates or endoscopic healing in IBD. Preclinical tier: Over 30 rat studies document healing in cysteamine colitis, NSAID injury, colocutaneous fistulas, and ileoileal anastomosis models. Doses as low as 10 ng/kg improved outcomes when given orally or intraperitoneally. These prove consistent tissue repair in controlled animal settings but do not prove the same in humans. Anecdotal tier: Reddit threads in r/UlcerativeColitis contain mixed reports. Some users describe reduced flares after oral or injectable use; others report no change after months of use and thousands of dollars spent. X posts echo similar personal stories without controlled verification.\n\n## What scientists say\n\nResearchers from the originating group describe BPC-157 as stable in human gastric juice for over 24 hours and effective across upper and lower GI tract models. Reviews note its interaction with nitric oxide pathways and growth factor expression that may aid angiogenesis and collagen formation. Independent gastroenterologists emphasize the absence of large-scale published human IBD data and advise against routine recommendation pending further trials. Toxicology studies in animals reached no lethal dose, supporting a wide safety margin in those models.\n\n## What people say on Reddit\n\nUsers share experiences ranging from noticeable symptom relief within weeks to complete lack of effect. Several threads caution that BPC-157 lacks FDA approval and published phase III data for IBD. One post referenced an open FDA docket and urged patients with positive experiences to submit comments. Others note concurrent use with conventional therapies and stress the importance of monitoring.\n\n## What people say on X\n\nPosts frequently link BPC-157 to gut repair claims based on animal literature. Some individuals report personal remission stories; others highlight ongoing clinical trial gaps or potential regulatory scrutiny. Discussions often reference the same rat fistula and colitis papers cited in scientific reviews.\n\n## What we do not know\n\nLong-term human safety beyond short trial windows remains uncharacterized. Optimal delivery route, duration, and patient selection criteria for IBD subtypes lack definition. Whether observed rat healing translates to sustained endoscopic remission in people is untested in adequately powered studies. Interaction with current IBD biologics or small molecules is undocumented.\n\n## Safety and limits\n\nAnimal data indicate low toxicity. Human phase II reports from decades ago claimed no side effects, but these lack independent confirmation. BPC-157 is not FDA-approved for any indication. Regulatory bodies continue to evaluate its status. Individuals considering research compounds should consult clinicians and review current legal status in their jurisdiction.","claims":[{"id":"c1","text":"BPC-157 accelerated healing in rat models of colitis, fistulas, and intestinal anastomosis.","section":"Why BPC-157 might help you","tier":"preclinical","source_ids":["s9","s10","s16"],"source_status":"sourced","why_material":"Demonstrates repair pathway activity in IBD-relevant injury models.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Early phase II trials tested BPC-157 in ulcerative colitis but detailed large-scale published results are unavailable.","section":"What the evidence actually shows","tier":"human","source_ids":["s14","s15","s20"],"source_status":"sourced","why_material":"Clarifies the limited scope of existing human data versus claims.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Over thirty rat studies show consistent cytoprotective and healing effects in GI damage models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s10"],"source_status":"sourced","why_material":"Quantifies the preclinical evidence base.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report mixed outcomes with BPC-157 for UC symptoms, including both improvement and no effect.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s24","s25","s26"],"source_status":"sourced","why_material":"Captures real-world user experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"BPC-157 remains unapproved by the FDA with no robust published phase III IBD efficacy data.","section":"Safety and limits","tier":"human","source_ids":["s15","s6"],"source_status":"sourced","why_material":"Sets regulatory and evidence boundaries clearly.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:57:50.012Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22300085/","title":"Stable gastric pentadecapeptide BPC 157","quote":"BPC 157 ... may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects.","link_status":"ok","quote_status":"unverified"},{"id":"s10","type":"pubmed","url":"https://journals.lww.com/ajg/fulltext/2025/10002/s808_oral_peptide_bpc_157_an_emerging_adjunct_to.809.aspx","title":"S808 Oral Peptide BPC-157—An Emerging Adjunct to...","quote":"In preclinical models, BPC-157 improved functional and structural outcomes in inflammatory bowel disease...","link_status":"http_403","quote_status":"unverified"},{"id":"s14","type":"other","url":"https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger","title":"BPC-157: Miracle Healing Peptide or Hidden Danger?","quote":"Older European trials: BPC-157’s discoverers in Europe have claimed success in early clinical trials for inflammatory bowel disease in the 1990s.","link_status":"ok","quote_status":"unverified"},{"id":"s15","type":"other","url":"https://www.guthealthdubai.com/can-bpc-157-heal-your-gut-a-dubai-gut-doctors-honest-opinion/","title":"Can BPC 157 Heal Your Gut?","quote":"There are zero robust, published human clinical trials for IBD.","link_status":"ok","quote_status":"verified"},{"id":"s16","type":"pubmed","url":"https://jpp.krakow.pl/journal/archive/10_13/articles/09_article.html","title":"stable gastric pentadecapeptide bpc 157 heals cysteamine...","quote":"BPC 157 induced an efficient healing of both at the same time...","link_status":"ok","quote_status":"unverified"},{"id":"s20","type":"other","url":"https://www.youtube.com/watch?v=HfJH-qIzeqA","title":"Can BPC-157 Fix Your Gut and Joints?","quote":"The most notable human studies involving BPC-157 pertain to its potential treatment for inflammatory bowel disease (IBD), particularly mild to moderate ulcerative colitis.","link_status":"http_429","quote_status":"unverified"},{"id":"s24","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1qpjb64/any_tried_bpc_157_peptides/","title":"Any tried BPC 157 peptides?","quote":"There is absolutely no reliable evidence this works in humans for management of IBD, no published phase II or greater clinical trials...","link_status":"ok","quote_status":"unverified"},{"id":"s25","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1cd99ol/battling_ulcerative_colitis_with_bpc157/","title":"Battling Ulcerative Colitis with BPC-157","quote":"Anti-inflammatory properties: BPC-157 has been shown to reduce inflammation... Limited clinical trials...","link_status":"ok","quote_status":"unverified"},{"id":"s26","type":"reddit","url":"https://www.reddit.com/r/UlcerativeColitis/comments/1stmgxs/if_bpc157_helped_your_uc_please_comment_on_this/","title":"If BPC-157 helped your UC, PLEASE comment on this FDA...","quote":"Within a few weeks I noticed real improvement, and after about 2 months, I was back in remission.","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"other","url":"https://www.droracle.ai/articles/298681/is-bpc-157-body-protection-compound-157-effective-as","title":"BPC 157 is Not Recommended for Crohn's Disease...","quote":"Most studies are limited to animal models · Only phase II clinical trials for inflammatory bowel disease have been conducted","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":17466,"tokens_out":3021,"cost":0.029385,"prev_hash":"genesis","hash":"0ae632aa0172712bf6bb24e94b6f0d52beac4fa066aa5b96e6e8f589a598a037"}],"provenance":[{"ts":"2026-06-29T21:57:50.870Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: What Are Peptides for Ibd\nSlug: what-are-peptides-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\",\"section_headings\":[\"What's breaking down\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_sensitive + GLP-1 peptide: include ~4 lb spinal load per 1 lb lost when relevant.\",\"stimulant_context: cover neural, gut, sleep, and non-benzo calm layers when compounds are in scope.\",\"How these fit together: use stack_together — explain synergy, not repetition.\"]}","response":"{\"slug\":\"what-are-peptides-ibd\",\"title\":\"What Are Peptides for IBD\",\"body\":\"## What's breaking down\\n\\nInflammatory bowel disease involves ongoing damage to the intestinal lining. Chronic inflammation erodes the mucosal barrier. This leads to ulcers, fistulas, and poor healing of surgical connections. The balance tips toward degeneration when repair mechanisms cannot keep pace with ongoing injury from immune activity and environmental triggers. Standard approaches often focus on suppressing inflammation. Repair-focused research looks at compounds that may support the gut's own healing processes instead.\\n\\n## Why BPC-157 might help you\\n\\nIf your IBD features persistent mucosal ulcers and fistulas, BPC-157 has been studied in rat models of colitis and fistula formation. In those setups, the peptide accelerated closure of defects and improved tissue strength at anastomosis sites. If inflammation drives ongoing breakdown, animal data show reduced cytokine activity and better endothelial protection in damaged gut segments. If you have short-bowel or poor wound healing after surgery, the same rat studies reported faster recovery of intestinal continuity and collagen deposition. These outcomes point to cytoprotective effects that stabilize the lining under stress.\\n\\n## How these fit together\\n\\nThis article focuses on a single compound. BPC-157 targets mucosal repair layers directly. Other peptides sometimes discussed in broader stacks address immune modulation or vascular support, but they sit outside the current evidence scope for IBD.\\n\\n## What the evidence actually shows\\n\\nHuman tier: Early phase II trials (PL-10, PLD-116, PL14736) from the 1990s and 2000s tested BPC-157 in ulcerative colitis patients. Proponents reported safety and some benefit, yet detailed peer-reviewed results with large cohorts remain unpublished. No robust, modern randomized controlled trials confirm remission rates or endoscopic healing in IBD. Preclinical tier: Over 30 rat studies document","tokens_in":17466,"tokens_out":3021,"cost":0,"prev":"genesis","hash":"765761eb457793e80615bb1c9368b51466716e8486b4efc789547952b7fa10d7"},{"ts":"2026-07-17T02:43:32.414Z","model":"owner","action":"voxel_divide","prompt":"","input":"what-are-peptides-ibd","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"765761eb457793e80615bb1c9368b51466716e8486b4efc789547952b7fa10d7","hash":"0fca23d9f867bd56d5cfeb6392e3227efa66df8b86737a90cf5708450ba88789"}],"energy":{"passes":2,"tokens_in":17466,"tokens_out":3021,"tokens_total":20487,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"0fca23d9f867bd56d5cfeb6392e3227efa66df8b86737a90cf5708450ba88789"},"posted_at":"2026-06-29T21:33:57.381Z","created_at":"2026-06-29T21:33:57.381Z","updated_at":"2026-07-17T02:43:32.414Z","machine":{"shape":"article.machine/v1","slug":"what-are-peptides-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/what-are-peptides-ibd","json":"https://miscsubjects.com/api/articles/what-are-peptides-ibd","bundle":"https://miscsubjects.com/api/articles/what-are-peptides-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":10,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/what-are-peptides-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=what-are-peptides-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/what-are-peptides-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"what-are-peptides-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/what-are-peptides-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/what-are-peptides-ibd","json":"/api/articles/what-are-peptides-ibd","markdown":"/api/articles/what-are-peptides-ibd/bundle?format=markdown","skill":"/api/articles/what-are-peptides-ibd/skill","topology":"/api/articles/what-are-peptides-ibd/topology","versions":"/api/articles/what-are-peptides-ibd/revisions","invocations":"/api/articles/what-are-peptides-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"what-are-peptides-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"f313343e9fc6543df1ca1da0ba6ee1849dc2572dc554c93d7f36482d7e48dbf3"}}}